BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37322389)

  • 1. Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma.
    Lu H; Zhang B; Xie Y; Zhao W; Han W; Zhou L; Wang Z
    Invest New Drugs; 2023 Aug; 41(4):564-578. PubMed ID: 37322389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
    Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
    Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
    Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
    Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
    Liang Y; Bollen AW; Aldape KD; Gupta N
    BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
    Hou Z; Wu H; Luo N; Li S; Zhang X; Dong S; Zhu D; Zhang H; Tao R
    Oncologist; 2023 May; 28(5):449-452. PubMed ID: 36913260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.
    Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R
    J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.
    Pinheiro KV; Thomaz A; Souza BK; Metcalfe VA; Freire NH; Brunetto AT; de Farias CB; Jaeger M; Bambini V; Smith CGS; Shaw L; Roesler R
    Mol Biol Rep; 2020 Sep; 47(9):6817-6828. PubMed ID: 32862352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SETD2 Palmitoylation Mediated by ZDHHC16 in Epidermal Growth Factor Receptor-Mutated Glioblastoma Promotes Ionizing Radiation-Induced DNA Damage.
    Fan X; Sun S; Yang H; Ma H; Zhao C; Niu W; Fan J; Fang Z; Chen X
    Int J Radiat Oncol Biol Phys; 2022 Jul; 113(3):648-660. PubMed ID: 35192890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.
    Stein S; Zhao R; Haeno H; Vivanco I; Michor F
    PLoS Comput Biol; 2018 Jan; 14(1):e1005924. PubMed ID: 29293494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
    Yoshida Y; Ozawa T; Yao TW; Shen W; Brown D; Parsa AT; Raizer JJ; Cheng SY; Stegh AH; Mazar AP; Giles FJ; Sarkaria JN; Butowski N; Nicolaides T; James CD
    Mol Cancer Ther; 2014 Dec; 13(12):2919-29. PubMed ID: 25313012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
    Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
    J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
    Rong Y; Belozerov VE; Tucker-Burden C; Chen G; Durden DL; Olson JJ; Van Meir EG; Mackman N; Brat DJ
    Cancer Res; 2009 Mar; 69(6):2540-9. PubMed ID: 19276385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.
    Ramis G; Villalonga-Planells R; Serra-Sitjar M; Brell M; Fernández de Mattos S; Villalonga P
    Cell Oncol (Dordr); 2019 Aug; 42(4):521-536. PubMed ID: 30980364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
    Sepúlveda-Sánchez JM; Vaz MÁ; Balañá C; Gil-Gil M; Reynés G; Gallego Ó; Martínez-García M; Vicente E; Quindós M; Luque R; Ramos A; Ruano Y; Pérez-Segura P; Benavides M; Sánchez-Gómez P; Hernández-Laín A
    Neuro Oncol; 2017 Oct; 19(11):1522-1531. PubMed ID: 28575464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
    Taylor TE; Furnari FB; Cavenee WK
    Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
    Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
    Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.
    Binder ZA; Thorne AH; Bakas S; Wileyto EP; Bilello M; Akbari H; Rathore S; Ha SM; Zhang L; Ferguson CJ; Dahiya S; Bi WL; Reardon DA; Idbaih A; Felsberg J; Hentschel B; Weller M; Bagley SJ; Morrissette JJD; Nasrallah MP; Ma J; Zanca C; Scott AM; Orellana L; Davatzikos C; Furnari FB; O'Rourke DM
    Cancer Cell; 2018 Jul; 34(1):163-177.e7. PubMed ID: 29990498
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Wu S; Gao F; Zheng S; Zhang C; Martinez-Ledesma E; Ezhilarasan R; Ding J; Li X; Feng N; Multani A; Sulman EP; Verhaak RG; de Groot JF; Heffernan TP; Yung WKA; Koul D
    Clin Cancer Res; 2020 Mar; 26(6):1395-1407. PubMed ID: 31852834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.